Organisation mondiale de la santé (OMS) · Technical Documents

Polio Bulletin - 2017, Issue no. 9 (Week 17)

2 mai 2017 Organisation mondiale de la santé

Le texte intégral est hébergé par l’organisation qui le publie. lawenc.com indexe les métadonnées et renvoie vers la source officielle.

Texte intégral

2017 Issue No. 9 - Week 17 (as of 2 May 2017) HIGHLIGHTS April 2017 Meeting of the Strategic Advisory Group of Experts on Immunization The Strategic Advisory Group of Experts (SAGE) on Immunization met on 25-27 April 2017. As part of the meeting agenda the SAGE reviewed the progress in Polio eradication. The SAGE acknowledged the progress towards eliminating wild poliovirus transmission. Considering type 2 poliovirus withdrawal, SAGE expressed concern over the ongoing circulation of VDPV2 in Nigeria. Recognizing ongoing global inactivated polio vaccine (IPV) shortage, SAGE discussed the evidence of the role of IPV and made the following recommendations: 1. Regional and national immunization technical advisory groups should recommend two fractional IPV doses in national routine immunization schedule, where practical, provided that countries have access to appropriate IPV presentations (e.g. single dose or 5 dose-vials), the capacity to administer intradermal injections, and a good advocacy and communication plan for parents and healthcare providers; 2. IPV supply should be prioritized for use in routine immunization (especially in Tier 1 and 2 countries); 3. SAGE also requests that WHO reviews its tier classification of countries with respect to prioritization of IPV to take into account the size of the population with no IPV protection and the recent type 2 VDPV events. SAGE also discussed polio immunization policy after global OPV withdrawal and noted the progress in the implementation of biocontainment of poliovirus and the development of post-certification strategy. For more information, please visit: http://www.who.int/immunization/policy/sage 20% 100% CHN 16.9% 33.3% 0.0% 13.5% 1.3% 0.0% 5.0% 0% 5% 10% 15% 20% 25% 30% 35% 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 15 16 CHN 17 15 16 KHM 17 15 16 LAO 17 15 16 MYS 17 15 16 PHL 17 15 16 PNG 17 15 16 VNM 17 0% 15 16 CHN 17 15 16 KHM 17 15 16 LAO 17 15 16 MYS 17 15 16 PHL 17 15 16 PNG 17 15 16 VNM 17 20% 40% 60% 80%

Polio Bulletin

Chart 1. Non-polio AFP rate (per 100 000 persons < 15 years of age), 2015–2017* 100%

Chart 2. Adequate specimen collection rate, 2015–2017

* AFP rate annualized as of week 17

Chart 3. Percentage of reported AFP cases by number of polio vaccination doses, 2017

Chart 4. Percentage of reported AFP cases with pending classification > 90 days after onset, 2017

80%

KHM LAO MYS

60%

40%

PHL PNG VNM

CONTACT US Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization P.O. Box 2932, 1000 Manila, Philippines Phone: +63 2 5288001 Fax: +63 2 5211036, 5260279 Email: wproepidata@who.int Web: www.wpro.who.int/immunization/en

0% CHN KHM LAO MYS 1-2 doses

PHL 0 doses

PNG Unknown

VNM

≥ 3 doses

Note: Priority countries were selected for the charts. Official WHO acronyms have been used for abbreviation: CHN (China), KHM (Cambodia), LAO (Lao People’s Democratic Republic), MYS (Malaysia), PHL (Philippines), PNG (Papua New Guinea), and VNM (Viet Nam).

Table 1A. Classification of AFP cases with onset in 2016 and key surveillance indicators 2015 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate % % with investigated adequate ≤ 2 days of specimens 2 notification 3 ≥ 80% ≥ 80% Latest report date 4 Days since last report 5

2016 Indicators

Country/area

Poliocompatible

Discarded (Non-polio)

Total

> 90 days 1 # (%)

≥1

≤ 30

Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Japan Lao People's Democratic Republic Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam Pacific island countries and areas Total 1. 2. 3. 4. 5. 6.

53 3 84 5217 10 1 71 144 9 7 27 413 83 8 380 15 6525

45 1 45 2234 8 1 163 24 77 9 9 30 394 69 6 232 10 3357

62 1 51 5692 10 1 133 143 7 12 23 417 70 7 382 19 7030

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 3 6

1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1

61 1 50 5684 10 1 130 143 7 12 23 417 70 7 382 15 7013

0 0 1 8 0 0 0 0 0 0 0 0 0 0 0 4 13

0 (0.0%) 0 (0.0%) 1 (2.0%) 8 (0.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (21.1%) 13 (0.2%) Green Yellow Red

1.38 1.00 1.13 2.55 1.25 1.00 5.42 1.86 0.78 1.33 0.77 1.06 1.01 1.17 1.65 1.90 2.09

45% 100% 88% 92% 90% 100% 74% 80% 71% 58% 43% 71% 93% 100% 95% 68% 90%

95% 100% 92% 100% 100% 100% 92% 81% 100% 83% 91% 95% 100% 100% 91% 100% 98%

20-Mar-17 11-Jan-17 25-Apr-17 19-Apr-17 09-Jan-17 12-Jan-17 13-Mar-17 06-Mar-17 13-Mar-17 13-Mar-17 10-Apr-17 10-Mar-17 26-Apr-17 06-Jan-17 21-Apr-17 03-Apr-17

7 13 29 -

Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases investigated within two days of notification Report date is fixed as soon as all cases for the year have been classified Countries are expected to submit data at least once per month to WPRO Includes two cases that are 15 years old or older

Reached o r surpassed target Nearly reached target: 0.5–0.99 fo r no n-po lio A FP rate; 60–79% fo r o ther indicato rs Substantially belo w target

Polio Bulletin

Table 1B. Classification of AFP cases with onset in 2017 and key surveillance indicators 2016 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate 2 % % with investigated adequate ≤ 2 days of specimens 3 notification 4 ≥ 80% ≥ 80% Latest report date Days since last report 5

2017 Indicators

Country/area

Poliocompatible

Discarded (Non-polio)

Total

> 90 days 1 # (%)

≥1

≤ 30

62 1 51 5692 10 1 133 143 7 12 23 417 70 7 382 19 7030

45 1 45 2256 8 1 161 21 77 9 9 31 394 68 6 234 11 3377

11 0 3 921 0 0 21 37 2 5 6 76 15 1 60 3 1161

0 0 0 0 0 0 0 0 0 0 0 0 0 0

4 0 124 15 10 1 0 2 44 15 1 3 0 219

7 3 797 6 27 1 5 4 32 0 0 57 3 942

1 (9.1%) 1 (33.3%) 156 (16.9%) 0 (0.0%) 5 (13.5%) 0 (0.0%) 2 (40.0%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 3 (5.0%) 0 (0.0%) 169 (14.6%) Green Yellow Red

0.75 0.20 1.25 3.06 1.47 0.68 1.70 0.59 0.59 0.67 0.51 0.78 0.83 1.05

36% 67% 91% 90% 78% 100% 20% 67% 57% 87% 100% 88% 33% 87%

100% 67% 99% 86% 54% 100% 100% 100% 96% 100% 100% 95% 100% 97%

28-Apr-17 10-Apr-17 25-Apr-17 19-Apr-17 03-Apr-17 12-Apr-17 12-Apr-17 12-Apr-17 05-Apr-17 26-Apr-17 10-Apr-17 31-Mar-17 26-Apr-17 07-Apr-17 21-Apr-17 03-Apr-17

4 22 7 13 29 20 20 20 27 6 22 32 6 25 11 29 -

Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Annualized non-polio AFP rate per 100 000 population under 15 years of age Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases investigated within two days of notification Countries are expected to submit data at least once per month to WPRO

Reached o r surpassed target Nearly reached target: 0.5–0.99 fo r no n-po lio A FP rate; 60–79% fo r o ther indicato rs Substantially belo w target

Polio Bulletin

Table 2A. Laboratory investigation of stool samples from AFP cases with onset in 2016 and key laboratory indicators Results of virus isolation for AFP cases Country/area Polio laboratory Total no. of AFP cases with specimens L20B positive L20B positive + NPEV only NPEV % results % reported specimens Pending Latest Pending 14 days ≤ positive for report date ≤ 14 days > 14 days NPEV ≥ 80% Intratypic differentiation/ Sequencing 1 laboratory No. of isolates received Type 1 Wild Sabin VDPV Results of intratypic differentiation (ITD)/sequencing for virus isolates Type 3 Type 2 Wild Sabin VDPV Wild Sabin VDPV NPEV 2 1

Negative

Pending ITD

% ITD results Discordant reported ≤ 7 pending days of sequencing receipt ≥ 80%

Australia Brunei Darussalam Cambodia China (total) China, Anhui China, Beijing China, Chongqing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Guizhou China, Hebei China, Heilongjiang China, Henan China, Hubei China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Neimongol China, Ningxia China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Hainan China, Liaoning China, Qinghai China, Tibet China, Hong Kong SAR China, Macao SAR Japan Lao People's Democratic Republic Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam (North) Viet Nam (South) Pacific island countries and areas Total

VIDRL VIDRL NIID Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab PHLC PHLC NIID NIID IMR PHI IESR VIDRL RITM NIH SGH NIHE PI VIDRL

47 1 51 5613 321 44 84 182 99 406 321 223 362 119 453 200 248 239 226 89 110 21 122 397 41 158 387 42 110 251 188 44 90 30 6 10 0 201 139 7 10 24 461 69 7 208 167 16 7031

0 0 2 67 3 0 1 5 2 8 3 2 5 1 7 0 1 0 1 0 5 0 1 7 1 5 3 1 1 0 2 0 1 0 1 0 19 0 0 0 1 5 0 0 6 5 0 105

0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1

3 0 11 413 12 1 8 8 2 23 44 15 49 3 48 18 23 4 12 7 3 0 3 31 0 7 43 1 4 18 17 3 4 2 0 0 20 7 1 0 3 43 7 0 26 16 5 555

44 1 38 5123 306 43 75 169 94 374 274 206 308 115 398 180 224 235 213 82 101 21 115 359 40 146 341 40 105 232 169 41 85 28 4 10 163 132 6 10 20 413 62 7 176 146 11 6362

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 9 0 0 0 0 1 0 0 0 0 0 0 2 0 0 0 0 1 0 3 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 9

94% 100% 88% 96% 100% 100% 96% 99% 97% 88% 100% 98% 98% 99% 87% 97% 100% 99% 99% 100% 90% 95% 84% 95% 100% 97% 95% 100% 98% 95% 99% 91% 96% 92% 100% 96% 97% 100% 93% 100% 100% 98% 95% 100% 99% 96% 97% 95%

5% 0% 20% 6% 3% 2% 7% 4% 2% 4% 11% 6% 11% 3% 9% 9% 8% 2% 5% 6% 2% 0% 2% 6% 0% 4% 9% 2% 4% 6% 7% 6% 3% 5% 0% 0% 8% 5% 7% 0% 12% 7% 9% 0% 11% 9% 26% 6%

27-Jan-17 27-Jan-17 30-Jan-17 19-Apr-17

VIDRL VIDRL NIID Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC CCDC CCDC CCDC CCDC

0 0 3 163 5 0 3 11 10 19 6 8 10 1 18 0 2 0 2 0 10 2 2 12 4 13 6 2 4 0 5 1 4 1 2 0 0 40 0 0 0 2 14 0 0 7 14 0 243

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 43 1 0 5 0 7 2 2 5 0 7 0 1 3 0 0 1 0 4 0 2 0 0 1 1 1 0 18 0 4 1 2 68

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 4

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

2 16 0 0 0 3 1 0 2 0 0 0 0 0 0 0 0 2 2 0 2 0 2 2 0 0 0 0 3 0 3 0 2 26

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1 97 4 3 6 7 11 4 4 5 1 5 2 1 6 2 2 9 2 9 4 0 2 3 0 3 0 2 15 2 7 6 10 138

0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1

0 6 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

100% 99% 100% 100% 100% 89% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%

14-Feb-17 14-Feb-17 30-Jan-17 12-Jan-17 28-Jan-17 16-Jan-17 27-Jan-17 08-Mar-17 07-Mar-17 02-Feb-17 06-Jan-17 24-Jan-17 03-Feb-17

PHLC PHLC NIID NIID IMR NIID IESR VIDRL RITM NIH SGH NIHE PI VIDRL

1. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, China, Hong Kong SAR); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 2. NPEV growing in L20B cells

Polio Bulletin

Table 2B. Laboratory investigation of stool samples from AFP cases with onset in 2017 and key laboratory indicators Results of virus isolation for AFP cases Country/area Polio laboratory Total no. of AFP cases with specimens L20B positive L20B positive + NPEV only NPEV % results % reported specimens Pending Pending Latest 14 days ≤ ≤ 14 days > 14 days positive for report date NPEV ≥ 80% Intratypic differentiation/ Sequencing 1 laboratory No. of isolates received Type 1 Wild Sabin VDPV Results of intratypic differentiation (ITD)/sequencing for virus isolates Type 3 Type 2 Wild Sabin VDPV Wild Sabin VDPV NPEV 2 1

Negative

Pending ITD

% ITD results Discordant reported ≤ 7 days of pending receipt sequencing ≥ 80%

7 0 3 896 56 14 21 34 14 80 40 36 64 16 84 32 23 48 24 11 9 5 16 66 9 25 44 11 22 37 31 4 15 5 0 1 0 35 49 2 2 6 130 15 2 30 34 5 1217

0 0 13 1 0 1 1 0 1 1 0 2 0 1 0 0 0 1 0 0 0 1 1 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 14

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1 0 23 0 0 1 0 0 2 3 1 2 0 2 2 0 0 1 0 1 0 1 1 0 0 4 0 0 1 0 1 0 0 0 3 1 0 0 2 6 2 0 3 1 2 44

5 3 824 55 12 18 31 12 75 36 34 57 16 79 28 19 44 22 11 8 5 12 64 9 25 40 11 20 34 31 3 9 4 0 32 48 2 2 0 116 13 1 25 27 2 1100

1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 7 0 1 2 6 1 19

0 0 36 0 2 1 2 2 2 0 1 3 0 2 2 4 4 0 0 0 0 2 0 0 0 0 0 0 2 0 0 6 1 0 0 0 0 0 4 0 0 0 0 0 0 40

91% 100% 92% 98% 100% 85% 83% 100% 97% 100% 97% 99% 100% 77% 90% 100% 100% 100% 100% 100% 100% 57% 79% 100% 92% 81% 100% 100% 93% 100% 100% 100% 100% 100% 98% 100% 100% 100% 99% 93% 100% 98% 100% 100% 92%

27% 0% 2% 0% 0% 5% 0% 0% 2% 8% 3% 3% 0% 2% 7% 0% 0% 2% 0% 6% 0% 7% 1% 0% 0% 6% 0% 0% 1% 0% 13% 0% 0% 9% 2% 0% 0% 67% 4% 7% 0% 11% 4% 50% 2%

28-Apr-17 28-Apr-17 10-Apr-17 19-Apr-17

0 0 0 28 1 1 2 1 0 2 2 0 3 0 3 0 2 0 1 0 0 0 1 3 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 28

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

10 0 0 0 0 2 2 0 0 1 0 0 1 4 10

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

17 1 1 2 1 0 0 3 2 1 1 1 2 2 17

1 0 0 0 0 0 0 0 1 0 0 0 0 0 1

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

92% 0% 100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 100% 100% 92%

28-Apr-17 28-Apr-17 24-Apr-17 26-Apr-17 10-Apr-17 01-May-17 28-Apr-17 26-Apr-17 26-Apr-17 28-Apr-17 27-Apr-17 20-Apr-17 28-Apr-17

CCDC PHLC PHLC NIID NIID IMR NIID IESR VIDRL RITM NIH SGH NIHE PI VIDRL

Polio Bulletin

Table 3. Laboratory confirmation of polio isolates from environmental samples in 2016–2017 1 2016 Country/area Intratypic differentiation lab 2 Total number of samples processed Total number of samples with polio isolates Polio isolates Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin VDPV NPEV Pending ITD Discordant Total number pending of samples sequencing processed Total number of samples with polio isolates Type 1 Wild Sabin VDPV Wild

2017 Polio isolates Type 2 Sabin VDPV Wild Type 3 Sabin VDPV NPEV Pending ITD Discordant pending sequencing

Australia China (total) China, Fujian China, Gansu China, Guangdong China, Guangxi China, Heilongjiang China, Shandong China, Shanghai China, Xinjiang China, Yunnan Malaysia Total

VIDRL Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC IMR

0 345 60 13 48 36 45 45 24 36 38 10 355

171 12 8 35 13 21 28 18 36 0 0 171

0 0 0 0 0 0 0 0 0 0

179 3 5 19 1 0 25 17 109 179

0 0 0 0 0 0 0 0 0 0

174 1 5 4 4 5 15 4 136 174

0 0 0 0 0 0 0 0 0 0

507 11 13 62 52 46 42 34 247 507

0 0 0 0 0 0 0 0 0 0

229 42 2 39 23 32 40 18 25 8 6 235

0 0 0 0 0 0 0 0 0 0 0 0

0 30 0 3 8 8 0 5 0 6 0 2 32

19 0 1 6 3 0 3 0 6 0 0 19

0 0 0 0 0 0 0

19 1 2 2 3 11 19

0 0 0 0 0 0 0

93 7 11 7 12 56 93

0 0 0 0 0 0 0

44 0 0 8 8 0 14 0 14 0 0 44

0 0 0 0 0 0 0 0 0 0 0 0

1. Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IMR (Institute of Medical Research, Malaysia); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)

Table 4. Vaccine-derived poliovirus1 identified from laboratory testing2, 2000–2017 Country/area Cambodia

2000–2009 2006 - 1 Total - 2 2009 - 1 Total - 27

2010

2011

2012

2013

2014

2015

2016

2017

China

aVDPV2 (3 AFP + 1 contact + 1 non-AFP) aVDPV3 (1 AFP + 1 non-AFP)

aVDPV1 (1 AFP) aVDPV2 (2 AFP + 1 contact) cVDPV2 (2 AFP) iVDPV2 (1 AFP + 1 non-AFP) iVDPV3 (1 AFP)

aVDPV1 (1 AFP) aVDPV2 (2 AFP) cVDPV2 (2 AFP + 1 contact) iVDPV2 + iVDPV3 (1 AFP)

aVDPV2 (1 non-AFP) iVDPV2 + iVDPV3 (1 AFP)

aVDPV1 (1 non-AFP) aVDPV2 (2 AFP) iVDPV3 (1 AFP)

aVDPV1 (1 AFP) aVDPV2 (1 AFP) iVDPV2 (1 AFP)

aVDPV3 (1 AFP)

?VDPV3 (1 AFP)

China, Hong Kong SAR Japan Lao People's Democratic Republic Mongolia Philippines Viet Nam

2005 - 3 2005 - 1 Total - 2 2004 - 3 2003 - 1 2001 - 3 aVDPV2 (2 AFP) aVDPV2 (1 AFP) cVDPV1 (8 AFP + 21 contacts) cVDPV1 (3 AFP + 4 contacts)

1. Prefix letter refers to the VDPV category: "cVDPV" = circulating VDPV, "iVDPV" = immunodeficiency-associated VDPV, "aVDPV" = ambiguous VDPV, "?VDPV" = pending. Suffix number refers to the poliovirus serotype (types 1, 2 or 3). 2. Source of specimens could be AFP cases, contacts, or non-AFP cases 3. Refers to year of last VDPV case, and aggregate total of VDPV cases for 2000-2009 4. Based on laboratory reporting only; not yet classified by AFP surveillance

Polio Bulletin

Informations clés

Organisation Organisation mondiale de la santé (OMS)

Type de document Technical Documents

Date d'adoption 2 mai 2017

Source Organisation mondiale de la santé